Last updated: December 24, 2025
Executive Summary
NDC 70677-1173 refers to Ocrevus (ocrelizumab), a monoclonal antibody developed by Roche, primarily indicated for multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS). As a high-cost biologic with significant market penetration, understanding current market dynamics, competitive landscape, and future price trajectories is crucial for stakeholders.
This report provides an in-depth analysis of the current market environment, pricing trends, competitive factors, regulatory landscape, and forecast projections for Ocrevus over the next five years.
1. Drug Overview
| Attribute |
Details |
| NDC |
70677-1173 |
| Brand Name |
Ocrevus |
| Manufacturer |
Roche |
| Therapeutic Class |
Monoclonal antibody, immunomodulator |
| Indication |
MS (relapsing and primary progressive), PPMS |
| Approval Date |
2017 (FDA) |
| Currently Approved Uses |
Multiple sclerosis (MS), PPMS |
2. Market Landscape
2.1. Epidemiology
- Multiple sclerosis (MS) affects approximately 2.8 million people worldwide, with approximately 1 million in the U.S. alone.
- PPMS accounts for roughly 10-15% of MS cases, estimated at ~150,000 in the U.S.
2.2. Market Penetration & Adoption
- As of 2023, Ocrevus holds a market share of approximately 35-40% among first-line MS biologics in the U.S.
- Primary competitors include Novartis’ Kesimpta (ofatumumab), Biogen’s Tysabri, and Teva’s Copaxone.
- Pricing Strategy: Average Wholesale Price (AWP) for Ocrevus varies by dose and indication but generally sits around $65,000 - $75,000 per year per patient.
| Year |
Estimated U.S. Sales |
Market Share |
Key Competitors |
Number of Patients (Estimated) |
| 2022 |
$2.4B |
39% |
Kesimpta (Novartis), Tysabri (Biogen) |
~100,000 |
| 2023 |
$2.6B |
40% |
Same |
~105,000 |
Note: Exact figures depend on prescription data and payer coverage.
3. Price Trends and Factors Impacting Pricing
| Key Factors |
Impact on Price |
Notes |
| Patent Exclusivity |
Maintains premium pricing |
Patent expiry expected beyond 2028 |
| Biosimilar Competition |
Pressure to reduce prices |
No biosimilars approved yet in U.S., but imminent biosimilar entries from South Korea and Europe projected post-2024 |
| Payer Negotiations & Rebates |
Can lower net prices |
Rebates can reduce net price by 20-40% |
| Regulatory & Policy Changes |
Potential price regulation |
CMS and private payers seeking value-based pricing models |
| Clinical Value & Convenience |
Justifies premium |
Ocrevus’s dosing schedule (bi-annual infusion) offers convenience |
4. Regulatory & Reimbursement Landscape
| Policy/Regulation |
Effect |
Implementation Date |
| Medicare Part B Pricing Updates |
Potential for negotiated pricing |
2023-2025 |
| Medicaid Drug Rebate Program |
Rebate requirements influence net prices |
Ongoing |
| Biosimilar Pathway & Approval (FDA) |
Increased competition |
Biosimilar approval projections vary but expected within 2-3 years |
5. Competitive Analysis and Market Share Dynamics
| Competitor |
Product Name |
Indications |
Approximate Market Share |
Price Range |
Key Differentiators |
| Novartis |
Kesimpta (ofatumumab) |
Relapsing MS |
15-20% |
$60,000 |
Subcutaneous administration |
| Biogen |
Tysabri (natalizumab) |
MS |
10-12% |
$70,000 |
Infusion-based, high efficacy |
| Teva |
Copaxone |
MS |
8-10% |
$55,000 |
Oral formulation (discontinued in US), injectable |
6. Price Projections (2023-2028)
| Year |
Expected List Price Range |
Influencing Factors |
Notes |
| 2023 |
$65,000 - $75,000 |
Market share stability, no biosimilars |
Slight inflation adjustment |
| 2024 |
$66,000 - $77,000 |
Potential biosimilar launches abroad |
Slight downward pressure |
| 2025 |
$67,000 - $78,000 |
Biosimilar entry in Europe/Canada |
Possible U.S. biosimilar approvals may influence prices |
| 2026 |
$67,500 - $79,000 |
Continued competition |
Pricing stabilization expected |
| 2027 |
$68,000 - $80,000 |
Policy/regulatory adjustments |
Market maturity |
Note: These are list prices; net prices after rebates are typically 20-40% lower.
7. Key Risks & Opportunities
| Risks |
Opportunities |
| Biosimilar erosion post-2024 |
Market share expansion in emerging markets |
| Government price regulation |
Development of next-generation formulations |
| Patent expiry pressures |
Strategic partnerships and lifecycle management |
| Payer negotiation hurdles |
Increasing clinical value propositions |
8. Comparative Price and Market Data Table
| Product |
Indication |
Price Range (USD) |
Approvals & Notes |
Market Share (2023) |
| Ocrevus (NDC 70677-1173) |
MS, PPMS |
$65K - $75K |
Approved 2017 |
39-40% |
| Kesimpta |
Relapsing MS |
~$60K |
2020 |
15-20% |
| Tysabri |
MS |
~$70K |
2004 |
10-12% |
| Copaxone |
MS |
~$55K |
1996 |
8-10% |
9. Conclusions and Outlook
- Market Position: Ocrevus remains a premium biologic with strong market penetration due to its efficacy in both relapsing and progressive MS.
- Pricing Trends: List prices are expected to increase marginally (~1-2%) annually through 2028, driven by inflation and sustained demand.
- Competitive Pressure: Biosimilars and emerging therapies (such as oral agents and subcutaneous options) pose future pricing and market share risks.
- Strategic Implications: Manufacturers and payers must balance access, affordability, and clinical value, potentially leveraging value-based contracts.
Key Takeaways
- Ocrevus (NDC 70677-1173) maintains a leading position in MS biologic therapy with list prices around $70,000.
- Market share is stable, but imminent biosimilar entries may pressure prices locally and internationally.
- Policy shifts towards value-based pricing and rebates influence net payer costs more than list prices.
- Future price projections suggest modest annual growth, with potential dips given biosimilar competition.
- Stakeholders should monitor regulatory changes, biosimilar developments, and payer strategies for informed decision-making.
FAQs
Q1: How does Ocrevus compare in price to its competitors?
Ocrevus’s list price ($65K–$75K) is within the higher range for MS biologics, comparable to Tysabri but more expensive than Copaxone. Biosimilar entries may lower prices in the future.
Q2: What factors could significantly reduce Ocrevus’s prices?
Biosimilar approvals, increased payer negotiations, and regulatory price caps could reduce net prices by up to 40%.
Q3: How does the patent landscape influence future pricing?
Patent expiry beyond 2028 allows biosimilar competition, which is projected to lead to significant price reductions in subsequent years.
Q4: Are there upcoming regulatory changes expected to impact Ocrevus pricing?
Yes. CMS initiatives and potential legislation favoring value-based pricing could pressure list prices and reimbursement models.
Q5: What is the outlook for Ocrevus’s market share through 2028?
Market share is expected to stabilize around 35-40%, with some drawdown expected as biosimilars and alternative therapies gain approval and uptake.
References
- FDA approval history and indications for Ocrevus (2017).
- IMS Health data on MS market and biologic utilization (2022-2023).
- Medicare and Medicaid policy updates (2023).
- Roche corporate disclosures and investor presentations (2022-2023).
- Industry analyses on biosimilar pathways and market forecasts (2023).
Note: All projections are estimates based on current trends, market data, and regulatory developments as of early 2023.
